$7.20 Million in Sales Expected for Aptevo Therapeutics Inc (NASDAQ:APVO) This Quarter

Equities research analysts forecast that Aptevo Therapeutics Inc (NASDAQ:APVO) will report $7.20 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Aptevo Therapeutics’ earnings, with the lowest sales estimate coming in at $6.90 million and the highest estimate coming in at $7.50 million. Aptevo Therapeutics reported sales of $6.83 million in the same quarter last year, which would suggest a positive year over year growth rate of 5.4%. The company is scheduled to report its next quarterly earnings report on Thursday, August 8th.

According to Zacks, analysts expect that Aptevo Therapeutics will report full year sales of $29.01 million for the current financial year, with estimates ranging from $28.00 million to $30.02 million. For the next year, analysts forecast that the company will post sales of $35.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that follow Aptevo Therapeutics.

Aptevo Therapeutics (NASDAQ:APVO) last announced its earnings results on Thursday, May 9th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.44). Aptevo Therapeutics had a negative net margin of 199.24% and a negative return on equity of 122.33%. The company had revenue of $7.02 million during the quarter, compared to analyst estimates of $6.30 million.

Several brokerages have issued reports on APVO. Piper Jaffray Companies dropped their target price on shares of Aptevo Therapeutics from $8.50 to $4.00 and set an “overweight” rating on the stock in a report on Wednesday, March 13th. Zacks Investment Research upgraded shares of Aptevo Therapeutics from a “hold” rating to a “buy” rating and set a $1.00 target price on the stock in a report on Thursday, March 14th. ValuEngine upgraded shares of Aptevo Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, April 5th. Finally, Roth Capital reiterated a “buy” rating on shares of Aptevo Therapeutics in a report on Thursday, May 23rd. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $7.88.

Shares of Aptevo Therapeutics stock opened at $0.88 on Wednesday. The company has a current ratio of 3.15, a quick ratio of 2.91 and a debt-to-equity ratio of 0.60. Aptevo Therapeutics has a 1 year low of $0.67 and a 1 year high of $5.83. The business’s 50-day simple moving average is $0.81. The company has a market cap of $43.08 million, a PE ratio of -0.37 and a beta of 2.24.

In other news, CEO Marvin L. White bought 50,000 shares of the company’s stock in a transaction on Friday, June 14th. The stock was bought at an average cost of $0.88 per share, with a total value of $44,000.00. Following the transaction, the chief executive officer now directly owns 293,603 shares in the company, valued at approximately $258,370.64. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Over the last ninety days, insiders acquired 196,667 shares of company stock valued at $161,200. 11.74% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Acadian Asset Management LLC lifted its position in shares of Aptevo Therapeutics by 4.8% during the fourth quarter. Acadian Asset Management LLC now owns 462,824 shares of the biotechnology company’s stock valued at $587,000 after buying an additional 21,059 shares during the last quarter. Clifford Swan Investment Counsel LLC purchased a new position in shares of Aptevo Therapeutics in the 4th quarter valued at approximately $35,000. Dimensional Fund Advisors LP raised its position in shares of Aptevo Therapeutics by 1.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,442,049 shares of the biotechnology company’s stock valued at $1,831,000 after purchasing an additional 16,482 shares during the last quarter. Deutsche Bank AG raised its position in shares of Aptevo Therapeutics by 251.7% in the 4th quarter. Deutsche Bank AG now owns 330,200 shares of the biotechnology company’s stock valued at $419,000 after purchasing an additional 236,300 shares during the last quarter. Finally, Marshall Wace LLP purchased a new position in shares of Aptevo Therapeutics in the 1st quarter valued at approximately $33,000. 36.37% of the stock is owned by institutional investors.

About Aptevo Therapeutics

Aptevo Therapeutics Inc, a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations.

Featured Article: Options Trading – Understanding Strike Price

Get a free copy of the Zacks research report on Aptevo Therapeutics (APVO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aptevo Therapeutics (NASDAQ:APVO)

Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.